Methods of obtaining tumor-specific T cell receptors
AssigneesHryz (Shanghai) Biotech Co., Hryz (Guangzhou) Biotech Co.
InventorsXiangjun Zhou, Yanyan Han, Xihe Chen
Life of this patent
Estimating the term…
Abstract
Provided methods of obtaining a plurality of T cell receptors specifically recognizing a target tumor antigen peptide from an individual that has clinically benefitted from an immunotherapy, such as Multiple Antigen Specific Cell Therapy. Also provided tumor-specific TCRs, engineered immune cells expressing the TCRs and methods of treating a disease using the engineered immune cells.
Claims20
A method of treating a cervical cancer comprising RGS5 in an individual, comprising intravenously administering to the individual an effective amount of a pharmaceutical composition comprising an engineered immune cell comprising a tumor-specific T-cell receptor (TCR) and a pharmaceutically acceptable carrier, wherein the TCR binds to an epitope of RGS5 comprising the amino acid sequence of SEQ ID NO:
- 82 or SEQ ID NO:
- 83, wherein the engineered immune cell is from the same individual, and wherein the TCR is selected from the group consisting of the following TCRs:
- (a) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 254, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 255, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 28;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 256, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 257, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 31;
- (b) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 258, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 259, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 34;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 260, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 261, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 37;
- (c) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 262, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 263, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 40;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 264, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 265, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 43;
- (d) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 266, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 267, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 46;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 268, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 269, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 49;
- and
- (e) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 270, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 271, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 52;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 272, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 273, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 55.
Dependencies are inferred from the claim text.